Tests and monitoring

New long‑term and real‑world data for risankizumab and upadacitinib were presented at ACG 2026, which may influence treatment considerations for people with difficult‑to‑treat Crohn's disease and ulcerative colitis.

The study suggests that using Advice & Guidance instead of elective referral was associated with a longer time to diagnosis for IBD, which could influence how primary care referral pathways are evaluated or designed.

Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Capsule Endoscopy. The original article is from gastroendonews.com.

New Phase 3 and long‑term analyses presented at ACG 2026 report that risankizumab and upadacitinib showed disease control in patients with moderate‑to‑severe IBD, including difficult‑to‑treat Crohn’s disease. These...

The study points to a possible noninvasive brain-based biomarker that correlates with intestinal fibrosis severity in Crohn’s disease, a complication that’s hard to detect and treat. This could eventually help identify...

MRE is a noninvasive imaging test commonly used to evaluate small-bowel Crohn’s disease, especially when disease is beyond the reach of endoscopy or when repeated follow-up imaging is needed. It helps detect...

AMNs are rare but can be malignant and may mimic UC flares or appendicitis, which can delay diagnosis. For people with long-standing UC, awareness may prompt appropriate imaging and surgical referral.

Cure8 could only read part of this source from einnews.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Tests and monitoring.

Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Infliximab, and Anti-TNF. The original article is from Frontiers in pediatrics.

The study suggests pulmonary nodules are more common in people with Crohn’s disease and that age and certain medications (not disease phenotype) may better predict nodule burden — information that could influence how...

Based on the title and source metadata, this appears to be a basic science related to Inflammatory bowel disease and Tests and monitoring. The original article is from Cell Research.

Knowing ustekinumab levels and anti-drug antibody status may help predict which people with Crohn’s disease are more likely to be in clinical remission and guide treatment adjustments.

Standardized, automated severity stratification at diagnosis could help guide early treatment planning and comparability across centers. An AI approach that approximates expert consensus may reduce variability in initial...

This study links higher mucosal PD-L1 expression to active IBD and routine disease activity measures, suggesting the PD-1/PD-L1 immune checkpoint may be involved in intestinal inflammation and could be a biomarker or...

A reliable blood biomarker that predicts relapse while a person with UC is in remission could help tailor monitoring intensity and treatment decisions.

Microbiological differences in Crohn’s-related abscesses could affect empirical antibiotic choices and highlight the importance of culture-directed therapy, especially in patients on immunosuppression who showed higher...

Adherence affects how well advanced IBD treatments work. Knowing which drug forms and patient factors link to missed doses can help patients and clinicians plan support strategies.

Enteric hyperoxaluria increases risk of calcium oxalate kidney stones and kidney injury. Knowing how common EH is in Crohn's disease and after bariatric surgery helps identify who might benefit from screening and...

Internal fistulae can be clinically silent yet serious in long-standing Crohn's disease. Early cross-sectional imaging detected rare gastrocolic and duodenocolic fistulae in this patient, and elective combined surgery...

Automated, objective scoring of colonoscopy images could reduce variability in Mayo Endoscopic Score assignment and support treatment decisions and monitoring for people with ulcerative colitis.

These Day 1 scores aim to identify patients unlikely to respond to IV steroids so treatment can be escalated earlier; that could shorten delays to rescue therapy and potentially improve outcomes for people admitted with...

A simple blood marker (LBP) that reflects bacterial exposure across the gut barrier was linked to disease severity and immune activity at diagnosis and during follow-up—especially in ulcerative colitis—so it might help...

Distinguishing Crohn’s disease from appendicitis is a common and important diagnostic problem. Objective CT measurements could help reduce subjective interpretation and guide correct diagnosis, but this study shows...

This study supports intestinal ultrasound as a noninvasive, accurate way to detect small-bowel Crohn's activity in many pediatric patients, which could reduce reliance on MRI for routine monitoring. It highlights...

This study suggests mirikizumab can maintain endoscopic and symptomatic improvements for up to two years in many patients with Crohn’s disease, and that IV reinduction can recover response in a subset of 1-year...

Faster, more sensitive capsule endoscopy reading could catch more Crohn’s-related ulcers that might otherwise be missed and reduce the time clinicians spend reviewing long video exams. However, AI increased false...

This national pediatric IBD network aims to collect clinical data and biological samples to study causes of early-onset IBD, track outcomes including intestinal healing and growth, and improve treatment strategies — work...

People with UC and PSC have limited study data on microbiome-targeted therapies; this trial asks whether short-course oral vancomycin is feasible and safe in this specific group and will look for early signals in...

Adherence to biologic therapy can affect how well treatment controls IBD; understanding whether self-administered subcutaneous vedolizumab has different adherence than IV infusion could influence treatment choices and...

Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease, Blood Test, and Tests and monitoring. The original article is from Canadian journal of gastroenterology &...

Noninvasive fecal tests can help detect intestinal inflammation without repeated endoscopy and support treat-to-target care. Better biomarkers could mean earlier treatment changes and less invasive monitoring for people...

The study documents shifting real-world prescribing for newly diagnosed IBD in Germany, with more biologic use and less mesalazine/thiopurine in recent years — changes that could affect treatment expectations and access.

The analysis suggests that some biologic and small-molecule therapies work differently depending on whether Crohn's disease affects the ileum, colon, or both — information that could help tailor long-term treatment...

A rapidly growing abdominal mass or unexplained systemic decline in someone with Crohn's disease may represent a rare malignancy (plasmablastic neoplasm) rather than infection or a disease flare; prompt biopsy is...

Accurate, consistent severity grading at diagnosis shapes initial treatment decisions in Crohn’s disease. AI that can reproduce expert severity assessments from small labeled datasets could help standardize grading and...

This study helps pinpoint which gut cell types and regulatory DNA regions are most likely to mediate genetic risk for Crohn’s disease, which can guide future research toward relevant cells and pathways.

If validated, early bedside ultrasound changes could let clinicians identify within days whether steroids or biologics are working, enabling faster treatment adjustments and potentially avoiding prolonged ineffective...

People with IBD or their clinicians may see signals suggesting certain drugs are more often reported with ulcerative colitis; this study combines adverse‑event reports with gene‑expression comparisons to help prioritize...

Patients with IBD—particularly those on anti‑TNF therapy and older adults—may have lower and faster‑waning antibody responses after mRNA COVID‑19 vaccination, which could affect timing or need for additional vaccine...

If local norepinephrine promotes neutrophil‑driven inflammation in UC, that could help explain disease progression in some patients and point to biomarkers (ADRB2‑rich neutrophils) that might predict response to anti‑TNF...

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Biomarkers. The original article is from Gastroenterology.

If you or your child is starting exclusive enteral nutrition (EEN) for pediatric Crohn’s disease, this review explains why outcomes vary and what tests and research might help predict who will benefit.

This study reports real-world short-term outcomes after colectomy for IBD at a tertiary New Zealand centre, including complication rates and how often restorative surgery (ileal pouch) was later performed—information...

Postoperative recurrence after ileocolonic resection is common and identifying who is at higher risk helps guide postoperative monitoring and decisions about early prophylactic therapy.

Food insecurity was linked with higher odds of having IBD and other GI conditions in a large U.S. survey, and many affected people lacked benefits or cancer screening. This matters because access to sufficient nutritious...

Patients with fibrostenosing Crohn’s disease face progressive strictures and limited targeted treatments; data from STENOVA’s OLE and the planned NOV‑ERA trial could advance therapies that target both inflammation and...

Faecal urgency is a frequent, disabling symptom in Crohn's disease that was common in this cohort and tied to poorer quality of life, mental-health burden, and more healthcare use over one year.

Pulmonary nodules appear more frequently in people with Crohn’s disease and have distinct patterns over time. Knowing which factors predict nodule burden can help clinicians prioritize monitoring and interpret chest...